PLOS mental health
2025
Óscar Andión, José Carlos Bouso, Jerome Sarris et al.
1 citation
Ayahuasca is a decoction native to the Amazon, where it plays a central role in the traditional medicine of many local cultures and has expanded internationally over the last decades. Ayahuasca has also attracted the interest of scientists for its potential benefits on mental health, but its adverse effects are under-researched. We analyzed data from the Global Ayahuasca Survey, including...
Revista Colombiana de psiquiatria
2025
Edgar A Estrella-Parra, José G. Avila-Acevedo, Ana M García-bores et al.
Ayahuasca is a psychotropic beverage from South America, derived from Banisteriopsis caapi and Psychotria viridis. The beverage contains alkaloids such as β-carbolines and dimethyltryptamine (DMT), which alter the psychoactive functions associated with perception and thought processes. Its consumption in the countries of origin, such as Brazil, Colombia, and Peru, is prevalent. Its use has been...
Current Addiction Reports
2025
Anahita Bassir Nia, Yalda Farahmand, Garret Griffith et al.
Despite national efforts to curb the opioid crisis, the clinical and societal challenges continue to grow. FDA-approved medications for opioid use disorder (OUD) are effective but are associated with high rates of treatment discontinuation and relapse. A collection of agents with acute effects on consciousness, collectively (if variably) categorized as 'psychedelics', have emerged as potential...
Drogues santé et société
2025
José López Sánchez, Silvia Mesturini Cappo
Cet article montre comment un onanya 1 shipibo travaillant dans le tourisme de l’ayahuasca perçoit, raconte et résiste à l’instrumentalisation de sa pratique. Respecter l’éthique propre à son savoir-faire et à son rôle nécessite, selon lui, non seulement une reconfiguration des pratiques, mais aussi une adaptation des discours. Il s’agit de répondre adroitement aux projections et aux attentes...
International review of neurobiology
2025
Caitlin M. DuPont, Matthew W. Johnson
6 citations
The current chapter presents the literature evaluating the effects of classic psychedelic treatments on five substance use disorders: alcohol, tobacco, opioid, stimulant, and cannabis. Most work on psychedelics and substance use disorders was conducted for alcohol use disorder. A range of classic psychedelics (LSD, psilocybin, and ayahuasca) appear to be beneficial for facilitating both reduced...
Journal of Psychoactive Drugs
2025
Jacob S. Aday, Emily K. Bloesch, Alan K. Davis et al.
16 citations
Qualitative studies and anecdotal reports suggest that experiences with ayahuasca, a psychedelic brew found in Central and South America, may be followed by individuals enduringly feeling more grateful and connected to nature. Yet, to date, these changes have been understudied. Here, participants (N = 54) completed validated surveys related to gratitude, nature relatedness, and nature...
Frontiers in Neuroanatomy
2025
Wigínio Gabriel de Lira-Bandeira, Lílian Andrade Carlos de Mendonça Batista, Andréa Silva de Medeiros Bandeira et al.
4 citations
The striatum (St) integrates cognitive, motor, and limbic functions and plays a critical role in processing emotions, motivation, and rewards. It may undergo several morphophysiological changes in neuropsychiatric diseases. Depression, a complex psychiatric disorder, affects millions of people around the world and leads to an increased risk of suicide, decreased quality of life, and functional...
Frontiers in Psychiatry
2025
Jonathan David, José Carlos Bouso, Maja Kohek et al.
correction
1. In the published article, there was an error. The error was regarding the average number of ayahuasca uses in the ayahuasca group in Study 1. A correction has been made to the Results section in lines 387-390. This sentence previously stated:Briefly, on average, our study participants have used ayahuasca (mean = 69.4 ± 98.7), 6.4 times more than psilocybin (mean = 10.7 ± 15.4, U = 1378, p <...